close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Atara Biotherapeutics, Inc.

< Previous 1 2 3 4 Next >
Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces Changes to Its Board of Directors
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate at the Stifel Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today